No Data
Needham Maintains Cara Therapeutics(CARA.US) With Buy Rating, Maintains Target Price $5
Needham analyst Joseph Stringer maintains $Cara Therapeutics(CARA.US)$ with a buy rating, and maintains the target price at $5.According to TipRanks data, the analyst has a success rate of 40.8% and a
Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS) and Cara Therapeutics (CARA)
Bearish Monday For Marijuana Stocks - Flower One Hldgs, SOL Glb Inv Among Top Gainers
GAINERS:Heritage Cannabis Holding (OTC:HERTF) shares closed up 63.64% at $0.001933 Industries (OTC:TGIFF) shares closed up 27.70% at $0.01Target Group (OTC:CBDY) shares closed up 19.19% at $0.01Rocky
Cannabis Stock Movers For May 17, 2024
GAINERS:Elixinol Wellness (OTC:ELLXF) shares closed up 116.00% at $0.01CordovaCann (OTC:LVRLF) shares closed up 29.04% at $0.07Heritage Cannabis Holding (OTC:HERTF) shares closed up 25.00% at $0.00Cha
Cannabis Stock Gainers And Losers From May 16, 2024
GAINERS:Flower One Hldgs (OTC:FLOOF) shares closed up 900.00% at $1e-05Cannabix Technologies (OTC:BLOZF) shares closed up 28.41% at $0.60Greenlane Hldgs (NASDAQ:GNLN) shares closed up 16.06% at $0.61C
HC Wainwright & Co. Reiterates Buy on Cara Therapeutics, Maintains $3.6 Price Target
HC Wainwright & Co. analyst Oren Livnat reiterates Cara Therapeutics (NASDAQ:CARA) with a Buy and maintains $3.6 price target.